Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Nodality Wins Backing From Pfizer Venture
by Lisa M. Jarvis
March 29, 2010
| A version of this story appeared in
Volume 88, Issue 13
Pfizer Venture Investments led a $15.5 million financing round for Nodality, a South San Francisco-based biotech firm developing personalized tests for cancer and autoimmune diseases. Laboratory Corp. of America, Kleiner Perkins Caufield & Byers, TPG Biotech, and Maverick Capital also participated in the round. Nodality was founded on flow cytometry technology devised by Stanford University professor Garry Nolan. The company is developing tests to help doctors determine which treatment is best suited for a particular patient. Its first product is aimed at people with acute myelogenous leukemia.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter